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Abstract
At the current time, the field of vaccinology remains empirical in many respects. Vaccine 
development, vaccine immunogenicity, and vaccine efficacy have, for the most part, historically 
been driven by an empiric “isolate-inactivate-inject” paradigm. In turn, a population-level public 
health paradigm of “the same dose for everyone for every disease” model has been the normative 
thinking in regard to prevention of vaccine-preventable infectious diseases. In addition, up until 
recently, no vaccines specifically had been designed to overcome the immunosenescence of aging, 
consistent with a post-WWII mentality of developing vaccines and vaccine programs for children. 
It is now recognized that the current lack of knowledge concerning how immune responses to 
vaccines are generated is a critical barrier to understanding poor vaccine responses in the elderly 
and in immunoimmaturity, discovery of new correlates of vaccine immunogenicity (vaccine 
response biomarkers), and a directed approach to new vaccine development.
The new fields of vaccinomics and adversomics provide models that permit global profiling of the 
innate, humoral, and cellular immune responses integrated at a systems biology level. This has 
advanced the science beyond that of reductionist scientific approaches by revealing novel 
interactions between and within the immune system and other biological systems (beyond 
transcriptional level), which are critical to developing “downstream” adaptive humoral and cellular 
responses to infectious pathogens and vaccines. Others have applied systems level approaches to 
the study of antibody responses (a.k.a. “systems serology”), [1] high dimensional cell subset 
immunophenotyping through CyTOF, [2, 3] and vaccine induced metabolic changes [4]. In turn, 
this knowledge is being utilized to better understand the following: identifying who is at risk for 
which infections; the level of risk that exists regarding poor immunogenicity and/or serious 
adverse events; and the type or dose of vaccine needed to fully protect an individual. In toto, such 
approaches allow for a personalized approach to the practice of vaccinology, analogous to the 
substantial inroads that individualized medicine is playing in other fields of human health and 
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medicine. Herein we briefly review the field of vaccinomics, adversomics, and personalized 
vaccinology.
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Introduction and Background
Vaccines have been one of the most effective public health strategies in preventing infectious 
diseases. A decade ago, we described the idea of vaccinomics and adversomics, based on the 
immune response network theory [5, 6], which utilizes immunogenetics/imunogenomics and 
systems biology approaches to understand the basis for inter-individual variations in 
vaccine-induced immune responses in human, as well as the basis for adverse side effects 
from vaccines [7]. Vaccinomics and adversomics explore the influence of genetic and non-
genetic regulation on the heterogeneity of vaccine-induced immune responses at both the 
personal and population level [5]. In particular, vaccinomics and adversomics utilize high-
throughput, high-dimensional systems biology approaches, which aim to predict variations 
in protective and maladaptive innate and adaptive immune responses to vaccines [6, 8]. In 
this regard, the basis of personalized (and predictive) vaccinology is the assessment of an 
individual’s genetic background, sex, as well as other factors that may impact vaccine 
immunogenicity, efficacy, and safety [8–11]. We and others have widely published on the 
applicability of the tools and concepts of vaccinomics, including immunogenetics and 
immunogenomics, to the knowledge-based directed development of new and improved 
vaccine candidates [12–15]. The application of these concepts is likely to allow for 
explanation, quantification, and prediction of vaccine-induced protective immune responses
—including the development of predictive immune signatures in response to vaccines. 
Indeed, we have previously published what we believe is the first draft of a mathematical 
model and predictive equation describing the non-random events that lead to a pre-
determined immune response [6]:
y= measure of immune response
βo= intercept
βi=coefficient for the ith variable xi and indicates the amount of change in y for a 1 
unit change in xi
E = random deviations from the model
We recognize that such an equation, given the current state of the science, is incomplete and 
cannot yet predict immune responses. But we present it as an early directional attempt to 
quantify such an equation. Such an approach begins to move us into a 21st-century model of 
directed vaccine development and an advanced understanding of how, and by what 
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mechanisms, vaccines and vaccine adjuvants trigger both useful and maladaptive innate and 
adaptive immune responses. We believe that vaccinomics and adversomics represent 
approaches counter to the standard methods of vaccine development until recently. 
Historically, vaccine development has been empirical, despite many emerging and re-
emerging complex, hyper-variable pathogens—many with elaborate immune escape 
mechanisms. In addition, vaccine coverage rates continue to suffer as society is risk-averse 
toward vaccines and demands levels of safety that may not be achievable. Finally, the “one-
size-fits-all” approach to the practice of vaccinology ignores the complexity and diversity of 
the human immune system and host genome. Thus, the promise of vaccinomics and related 
paradigms is to identify specific immune response profiles, immunosignatures, and 
biomarkers that predict vaccine safety and/or efficacy, and which may lead to new vaccine 
candidates.
Rationale and Examples of Vaccinomics and Adversomics
Vaccinomics provides the opportunity to examine not only immune response genes likely to 
be involved in vaccine response, but also the possibility of identifying the influence of new 
(uncharacterized) genes on vaccine-induced immunity. In turn, the identification and 
directed study of such genetic variants allows recognition, often at the molecular level, of the 
effects of differential binding, processing, and expression/presentation of antigenic viral 
peptides used in vaccine development, identification of the differential range of presented 
peptides (genetic restriction), altered secretion patterns (cytokines) in response to vaccines 
or vaccine adjuvants, altered transcription of important genes (signaling molecules) and gene 
products, altered binding of virus/antigens by membrane-based receptors (TLR, other), 
differential receptor function, expression, and affinities, and the impact of epigenetics on 
vaccine-induced immune responses. We have utilized this knowledge in our own laboratory 
to create a research-oriented paradigm of “discover-validate-characterize-apply,” which may 
be used in new candidate vaccine development (Fig. 1) [6]. In this paradigm, we have been 
able to utilize vaccinomics approaches to discover genetic variants that are significantly 
associated with subsequent downstream immune responses, validate that such variants are 
indeed associated, then seek to characterize the mechanism whereby such effects occur and, 
finally, apply this knowledge, often in functional studies, that confirm the effect on 
immunity. Such knowledge can be exploited in developing immune strategies to enhance or 
circumvent genetic restrictions, for example, in triggering vaccine-associated immune 
responses, by “reverse engineering” around a given genetic or other obstacle to generating 
protective immune responses.
There are a growing number of studies reporting unbiased genome-wide assessments of 
genetic variation and its influence on adaptive (humoral and cellular) vaccine-induced 
immune responses across multiple viral and bacterial vaccines. For example, candidate and 
GWAS immunogenetic and phamacogenetic studies have identified polymorphisms in HLA, 
KIR, MICA, and BTN genes associated with immune responses to pathogens causing 
disease in humans, such as hepatitis C [16], Mycobacterium leprae [17, 18], human 
immunodeficiency virus [19], and measles [20–22]. Similar studies have identified novel 
genes impacting immune responses to vaccines, including hepatitis B, rubella, influenza A, 
smallpox, anthrax, and mumps [23–33]. Our gene association studies of measles-mumps-
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rubella (MMR) vaccines have demonstrated that inter-individual variations in measles 
vaccine virus-induced humoral and cellular responses are significantly associated with 
polymorphisms in immune response genes and, together with HLA alleles, explain ~30% of 
the inter-individual variability in humoral response [5, 34–36]. These findings, which 
illustrated the importance of key HLA alleles in the adaptive humoral immune response to 
measles vaccine, led to the identification of naturally processed and presented measles-
derived peptides isolated from specific HLA polymorphisms associated with vaccine non- 
and hyper-response [37, 38]. These peptides containing specific components (adjuvants and 
biodegradable nanoparticles) are now being utilized in a reverse-engineering strategy to 
develop peptide-based candidate measles vaccines. Likewise, Homan et al. have attributed 
diminished protection to differential HLA presentation of T and B cell epitopes between 
vaccine and wild type strains of mumps virus [39]. This diminished efficacy could 
theoretically be overcome by incorporating defined critical immunogenic peptides into an 
improved vaccine.
TLR genes represent an important link between the innate and the adaptive immune system 
[40, 41]. As an example, we have demonstrated that measles vaccine-induced humoral 
responses are significantly associated with coding polymorphisms in the TLR2 (rs3804100) 
and TLR4 (rs5030710) genes [42]. For the rubella vaccine and TLR3 gene, a TLR3 gene 
SNP rs5743305 was associated with rubella-specific GM-CSF production [43]. Our recent 
mumps vaccine study has identified and replicated TLR4 SNPs associated with a ~45% 
decrease in antibody titer, and a TLR5 SNP associated with a 64% increase in T cell 
response (unpublished data). These data strongly suggest that robust TLR activation by 
measles, mumps, and rubella viruses is crucial for optimal vaccine response. Supporting 
these findings is a study demonstrating that an inactivated mumps vaccine containing a 
protollin-based TLR2/4 adjuvant is highly immunogenic in a mouse model; it lead to 
superior total IgG levels, higher neutralizing antibody titers, greater mucosal IgA 
production, and enhanced Th1/Th2 cytokine secretion [44]. One potential application of this 
finding is to identify the specific and critical interactions between TLRs (and other genes) 
and virus, leading to advances in our knowledge of the precise mechanisms driving 
immunity to MMR vaccine.
Sex-Based Differences in Immune Responses to Vaccines
Significant sex differences in humoral and cellular immune responses to vaccines are 
apparent [45, 46]. Additionally, local and systemic adverse rates are generally higher in 
females versus males. Protective antibody responses are significantly higher in females than 
males after vaccination against influenza, yellow fever, measles, mumps, rubella, hepatitis A 
and B, herpes simplex (HSV) 2, rabies, smallpox, and dengue viruses [47–55]. Sex-based 
differences in humoral immune responses are observed through various age groups [47–50, 
52–57], suggesting that sex steroid hormones are not the singular mediators of sex 
differences in humoral immune responses to vaccines [45, 58]. This suggests that genetic, or 
other, factors may be an important driver of sex-related differences in humoral immune 
response [59]. Despite significant evidence of immune response differences between the 
sexes, for the most part, vaccine studies have not examined and analyzed immune response 
outcomes by sex [60, 61]. In fact, little information is known about potential mechanisms for 
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sex-based effects, which should be a priority for vaccine research studies. Discovery of 
specific factors involved in sex-based differences in immune response may allow the 
identification of new correlates of vaccine immunogenicity.
In a cohort of 556 older (ages 50–64) and 558 younger (ages 18–49) previously vaccinated 
individuals, the seasonal trivalent influenza vaccine induced >1.5-fold higher A/H3N2-
specific HAI antibody titers in women than men across both age groups [47]. Similarly, a 
study of standard seasonal influenza vaccine and high-dose influenza vaccine responses in a 
sex-balanced cohort of 414 elderly subjects (ages 65–95) demonstrated significantly higher 
rates of seroconversion in females than in males [48]; however, no significant differences in 
antibody measures were found between males and females after seasonal influenza 
vaccination in another cohort of 158 older adults (ages 50–74) [62]. A study by Furman et 
al. examining gene expression, serum cytokines/chemokines, cell subsets, and 
phosphorylation events found several serum markers (LEPT, IL1RA, CRP, GMCSF, and 
IL5) to be more highly expressed in females than males after influenza vaccine [51]. This 
same report used a systems biology approach to identify a gene cluster involved in lipid 
biosynthesis that is regulated by testosterone and significantly correlated with poor humoral 
responses following influenza vaccination in men [51]. These data suggest that this gene 
cluster (e.g., genes involved in lipid metabolism) could be an important driver of sex-related 
differences in humoral immune response. This collective knowledge could substantially 
assist future personalized vaccine development efforts through the generation of new 
knowledge and the identification of targets and biomarkers that predict vaccine responses in 
specific populations (e.g., females vs. males; young vs. old; obese vs. lean). Further research 
is needed to clarify the effects of sex on immune response. Identification of molecular 
immune signatures of sex differences in innate and adaptive immune responses to vaccines 
may provide evidence necessary for additional efforts in designing personalized vaccination 
and vaccinomics approaches (i.e., in which males and females might be vaccinated 
differently using different doses or different vaccines) in an effort to provide equal 
protection while reducing side effects [46, 63, 64].
Immune Responses to Vaccines in the Elderly
A significant global public health issue is the aging of the population. As individuals age, 
immunosenescence develops, leading to poorer immune responses to vaccines. 
Immunosenescence is an age-related dysregulation of the immune system due to age-
associated changes in innate and adaptive immune system components, which leads to 
impaired immunity and protection following immunization or infection [65–67]. Published 
data reveal that innate and adaptive immunity is decreased with age, but the systems-level 
mechanisms for these findings are unclear [66, 68], particularly in regard to influenza and 
other viral vaccine responses where the morbidity, mortality, and associated healthcare costs 
are greater in older individuals [11]. Major signs of innate immune dysfunction commonly 
observed in the elderly include, but are not limited to, altered cytokine secretion; decreased 
NK cell activity; reduced TLR expression; and a chronic inflammatory state (elevated levels 
of IL-1β, MCP-1, TNF-α, and serum IL-6) known as “inflamm-aging” [8, 69–71]. Age-
related humoral immune dysfunction, for example, might be overcome through optimal 
stimulation of innate and/or Th cell-specific genes, which may be different in males and 
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females. For example, adjuvanted zoster subunit vaccine (Hz/su) reduced the risks of herpes 
zoster, and postherpetic neuralgia in immunocompetent persons 70 years of age and older 
[72]. This Hz/su vaccine contains varicella zoster virus glycoprotein E and a novel AS01B 
adjuvant system aimed to improve and preserve with age zoster-specific CD4+ T cell 
responses [73]. A TLR4 agonist GLA-SE (glucopyranosyl lipid adjuvant formulated in a 
stable emulsion) has been shown to enhance Th1 responses to influenza vaccine in older 
adults [74], suggesting a potential mechanism for targeting innate receptor agonists (e.g., 
TLRs) that enhance innate immune responses against influenza. Given the substantially 
diminished efficacy of influenza and other vaccines with age and the importance of 
developing improved vaccines [75], data from vaccinomics studies could be used to inform 
directed and rational development of next-generation influenza vaccines—potentially 
circumventing immunosenescence-related factors.
Systems biology approach provides a unique opportunity to identify biomarkers likely to be 
involved in immune responses to vaccination [8, 76, 77]. Fourati et al. applied a systems 
vaccinology approach to examine gene signatures and molecular pathways of age-related 
hyporesponse to hepatitis B vaccine (HBV) in naïve older adults [78]. They observed the B 
cell signaling pathway (and higher memory B cell frequencies) and inflammatory pathway 
(and increased frequencies of activated pro-inflammatory innate cells) were strongly 
correlated with higher and low antibody responses to HBV, respectively. This signature, 
including serum cytokine profiling and flow cytometric correlates of response, predicted the 
antibody response to HBV with up to 65% accuracy [78]. This study demonstrates that a 
systems biology approach can be used to predict age-related immune response to 
vaccination.
Obesity and Immune Responses to Vaccines
Obesity is another major public global health concern. In the US, 68% of adults and nearly 
32% of children and adolescents are now overweight or obese [79]. Weight gains across all 
countries have been demonstrated to be associated with increasing socioeconomic status. 
Obesity has been shown to be a predictor of impaired immunogenicity (e.g., decreased 
antibody response) to hepatitis B, tetanus toxoid, rabies, and influenza vaccines [80–83], and 
as such can be considered a marker, or state, of immunosuppression at its extremes. These 
data suggest that obesity is correlated with poorer vaccine-induced immune responses in 
humans, and further research is required to understand the immune mechanisms that are 
altered in obesity.
As individuals age, their circulating leptin levels rise with a concomitant reduction in leptin 
signaling; this results in leptin resistance, which is a finding associated with obesity [84]. 
Leptin resistance has been shown to adversely affect the immune response in obese subjects, 
including responses to influenza virus [85, 86]. For example, obese individuals demonstrate 
decreased activation of influenza-specific CD8+ T cells compared to healthy-weight 
persons, including decreased production of IFN-γ and granzyme B, suggesting that 
influenza vaccination may not be as effective in the obese population as in healthy-weight 
individuals [87]. Given only moderate seroprotection of influenza and other vaccines in 
obese older adults [83], and the importance of developing improved influenza vaccines [75], 
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systems biology studies designed to identify the mechanisms for improved immune response 
are needed. In fact, data from vaccine studies could be used to inform directed and rational 
development of personalized vaccines that optimally stimulate innate and adaptive immune 
responses in males and females and overcome immune deficiencies induced by obesity [88]. 
Careful vaccine studies comparing lean and obese persons could provide foundational data 
used to improve vaccine-induced protection in the obese, a subpopulation with an elevated 
risk for serious vaccine-preventable illnesses and suboptimal vaccine-induced protective 
responses [10].
Adversomics
Adversomics utilizes tools—much like those used in vaccinomics—to identify, characterize, 
and predict adverse, or maladaptive, immune responses to vaccines [6, 89, 90]. The promise 
of adversomics would be to develop or identify either predictors or immune signatures of 
maladaptive immune responses that lead to harm rather than benefit, and to better 
understand the generation and mechanisms of such maladaptive immune responses.
We have asked the question, as have other scientists, “does it make sense in the 21st century 
to give the same vaccine, dose, and at the same frequency to everyone, regardless of age, 
weight, gender, race, genotype, and medical condition?” For example, we give adult males 
and females the same dose, and the same number of doses of vaccines, ignoring the findings 
that females nearly always have superior humoral immune responses to males for all 
vaccines studied, and yet experience significantly more side effects—more adverse events, 
of greater duration, and of higher intensity [47, 55, 60].
While the field is young in implementation, research has already revealed associations 
between specific genes or SNPs and adverse immune outcomes. For example, associations 
between cytokine gene expression and fever after smallpox vaccine have been identified 
[91]. Other studies have demonstrated correlations between smallpox vaccine-induced fevers 
and IL-1A and IL-18 SNPs [92]. Other smallpox vaccine-induced adverse events such as 
fever, rash, and enlarged lymph nodes have been significantly associated with MTHFR, 
IRF1, and IL-4 SNPs haplotypes [93]. While smallpox vaccine is not used in the general 
population, such studies stand as examples of the usefulness of vaccinomic approaches. 
Finally, other recent studies have identified generic fever gene networks (TNF-alpha) after 
vaccine administration [94], and relationships between MMR vaccine administration and 
SNPs in IFI44L, CD46, SCN1A, 2A, and TMEM16 (ANO3) genes [95].
Challenges in Personalized Vaccinology
Despite the tremendous success of vaccines, vaccinologists face several current challenges, 
including difficulty in developing vaccines for hypervariable viruses (HIV, rhinovirus, 
hepatitis C virus, coronavirus) and complex pathogens (malaria, Mycobacterium 
tuberculosis); newly emerging pathogens, such as Zika virus (ZIKV); complications 
imposed by aging and immunosenescent populations; inadequate understanding of the 
neonatal and newborn immune systems; increasingly immune deficient or 
immunocompromised populations due to HIV, cancer, or medications; sex-based differences 
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in vaccine response and adverse-event rates; enhanced scrutiny of vaccine safety; and as 
noted global increases in age and weight. In addition, vocal and active anti-vaccine groups 
whose messages are not easily countered by facts or scientific studies have materially and 
detrimentally affected vaccine coverage rates [96–98]. Vaccinomic approaches can be 
utilized to better understand these issues; this information can then be used to inform new 
approaches, new understandings, and new vaccine candidates.
Just as new technologies have created exciting new opportunities in personalized medicine, 
they have brought with them novel challenges in addition to those mentioned above. In order 
for the full potential of personalized vaccines to be achieved, we must overcome additional 
challenges, such as the need for the following:
• Larger genotype:phenotype datasets (often in the many thousands to ten 
thousands)
• Integrating increasingly diverse high-throughput, high-dimensional data types
• Biomarkers that can reliably distinguish which product to give which people 
based on the likelihood of response or of an adverse side effect
• Vaccines with different mechanisms of action may require a move away from 
humoral correlates of protection for licensure; in this regard, correlates of 
protection based on cellular immune outcomes are likely to play an important 
role in future vaccines
• More sophisticated biostatistical and bioinformatics approaches that can identify 
patterns and causative networks within terabyte levels of extremely high 
dimensional data types
• From the economic side: methods of technology transfer and funding 
mechanisms to move novel vaccines developed through vaccinomic approaches 
into low and middle-income countries who often most need specific vaccines 
(malaria, others)
We have seen the shift from “vaccinology 1.0,” which is the empirical “Isolate-Inactivate-
Inject” paradigm, to “vaccinology 2.0”—the use of recombinant technology and novel 
adjuvants. However, even this paradigm is limited by our incomplete mechanistic 
understanding of adjuvants and innate immunity. As we adopt approaches such as those 
listed above, we envision a movement of the field into an era of “vaccinology 3.0,” during 
which we expect to see the use of vaccinomics and systems-level approaches to develop new 
vaccines; innovative vaccine-antigen packaging methods; and adjuvant development targeted 
at the innate response pathways best suited for a given pathogen.
A common reaction to this paradigm of personalized vaccinology is questioning cost and 
economics. At one level, such considerations are simply “too soon” in the development of 
the science to effectively answer. However, like progress being made in individualized 
medicine, it is likely that being able to provide the right vaccine to the right patient—for the 
right reasons and at the right dose—will lead to improved medical outcomes and reduced 
costs at the population level.
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Vaccine Development
Personalized vaccinology is the goal of applying the concept of personalized medicine to 
vaccines. Rapid strides in omics technologies and foundational work applying systems 
biology, computational immunology and reverse vaccinology have facilitated modern 
approaches to vaccine design and development enabling us to create vaccine formulations 
for new and re-emerging pathogens. Egg-based influenza vaccines take > 6 months to create. 
The recent licensure of cell culture-based influenza vaccines demonstrate that rapid, scalable 
processes can now be implemented in order to create vaccine against emerging influenza 
strains (e.g., H1N1, H5N1, H7N9, H9N2, H7N8) within weeks. [99] that can be safely 
administered to individuals with egg allergies is one example [100]. The Ebola outbreak in 
Liberia, Sierra Leone, and Guinea in 2015 provides another example [101]. DNA vaccines, 
virus-like particle vaccines, and replicating/non-replicating viral vector vaccines have all 
been created and tested. Among the most promising are a replication-competent, 
recombinant vesicular stomatitis virus vector expressing the glycoprotein of Ebola Zaire 
(rVSV-ZEBOV), [102] a variety of adenovirus-vectored vaccines expressing Ebola 
glycoprotein, [103, 104] a modified vaccinia virus Ankara-based vaccine encoding the Ebola 
Zaire glycoprotein (MVA-BN-Filo), [105, 106] and DNA-based vaccines—one expressing 
glycoproteins from both Zaire and Sudan, and the other expressing the Marburg glycoprotein 
[107]. Although the rVSV-based vaccine elicits high titers of neutralizing Ab, it is 
contraindicated in children and those with compromised immune systems. Viral vector 
vaccines present the problem of developing robust immunity to the vector as well as the 
target immunogen, limiting their usefulness to a single vaccination. The availability of 
vaccines in multiple vector backbones opens up the possibilities for prime-boost vaccination 
strategies for Ebola, similar to those that have been applied to HIV, malaria, and tuberculosis 
[108–111]. In this regard, a prime-boost regimen using the MVA-based vaccine as the 
booster vaccination has shown considerable promise [101].
Another example of modern vaccine development being applied to a new pathogen can be 
seen with the response to Zika virus. A purified, formalin-inactivated vaccine (ZIKV PIV) 
has been developed by the Walter Reed Army Institute of Research (WRAIR) [112] and is 
being evaluated in several clinical trials (NCT02963909, NCT02952833, NCT02937233), 
while other inactivated vaccines are in preclinical development [113]. Two variants of a 
plasmid DNA vaccine containing the prM-ENV proteins have been developed by NIAID and 
one of the formulations is currently in a phase I clinical trial (NCT02840487) [114]. Inovio 
Pharmaceuticals developed their own plasmid DNA vaccine (also expressing prM-ENV), 
which is currently in two clinical trials (NCT02809443, NCT02887482). RNA-based 
vaccines [115] and a variety of subunit and viral vector-based vaccines are also in 
development [113, 116, 117]. DNA and RNA-based vaccines can be rapidly made at 
minimal costs compared to other formulations and are fairly stable, without the cold-chain 
requirements of live virus-based vaccines.
Subunit vaccines are typically safer than whole virus-based products, which represents an 
active area of investigation not only for pathogens with no existing vaccines, but also for 
improving on established vaccines. Our group and others have identified pathogen-derived 
epitopes as preliminary steps in the development of safe, stable, and effective peptide- and 
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protein-based vaccines for smallpox, influenza, measles, tuberculosis, staphylococcus, and 
myriad other viral and bacterial pathogens [38, 118–122].
Parallel efforts by different groups to create new vaccines result in a spectrum of potential 
products that can be uniquely tailored to specific population groups. Live viral vaccines 
rapidly inducing robust immunity can be used in healthy individuals where time is of the 
essence (e.g., in outbreak scenarios), while inactivated or subunit vaccines can be used in 
vulnerable populations such as pregnant women or those with immunocompromising 
conditions, or in young children where the presence of maternal Ab interferes with whole 
virus vaccines. Vaccines based on different viral vector backbones can be combined into 
effective prime-boost regimens. Vaccines with specific adjuvants may be most appropriate 
for the elderly in order to overcome immunosenescence, or in the very young in order to 
compensate for immune system immaturity.
Conclusion
We, along with increasing numbers of other scientists, believe that personalized vaccinology 
will revolutionize the practice of vaccinology to the benefit of human health. As part of the 
development of this field of science, vaccinomics and adversomics will allow us to develop 
molecular immune signatures of adaptive and maladaptive immune responses to vaccines, 
develop early biomarkers of vaccine response in vaccine trials, identify who should get what 
vaccine and at what dose, and increase safety and public confidence in vaccines by reducing 
the likelihood of serious adverse events related to vaccines. In many ways, however, 
personalized vaccinology is most challenged by the difficulty in moving the field away from 
the post-WWII population-level paradigm of “one dose of every vaccine for everyone,” 
toward an individualized or personalized approach based on the unique factors relevant to a 
given individual. In his book, The Structure of Scientific Revolutions [123], Thomas Kuhn 
recognized that “we wrongly believe scientific progress is a process of linear accretion of 
knowledge, that science is predicated on the belief that the scientific community understands 
what the world is like, and that we suppress or resist ‘fundamental novelties’ because they 
are seen as subversive to our firmly held beliefs of what the world is like.” Later in his book, 
he suggests that “new advances always have and always will reveal that science and 
medicine includes bodies of belief incompatible with beliefs we hold today, and that 
advancements come when we reject a time-honored scientific theory in favor of another 
incompatible with it.” These cognitive biases have, in our opinion, been manifest in our 
discussions with scientific colleagues as we developed this field of science. Schopenhaur, 
the German philosopher, suggested that new discoveries are at first ridiculed, then opposed, 
and finally accepted as self-evident. Vaccinomics and adversomics appear to be moving 
from the ridiculed and opposed steps, and into the not-yet quite self-evident phase of the 
continuum.
Part of the challenge is that often the concept of personalized vaccinology suggests to the 
reader that a unique vaccine will be developed for each individual. While that is one tactic 
being used in the cancer-vaccine field, it is neither necessary nor practical for the prevention 
of infectious diseases. Rather, the personalized vaccinology approach would suggest the 
development of specific vaccines based on factors that relate to overcoming the potential for 
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poor immunogenicity and the potential for adverse events. An excellent example is influenza 
vaccines. A mere decade or so ago, only a trivalent injectable influenza vaccine was 
available. Quadrivalent vaccines were unavailable. For with one exception, everyone 
received the same vaccine and dose, regardless of age, weight, immunosuppression state, 
etc. At the current time in the US, multiple influenza vaccines are available so that the right 
vaccine, for the right patient, can be given at the right time. For example, LAIV can be used 
in younger subjects, or the needle-phobic. High-dose or MF-59 adjuvanted vaccines can be 
chosen for the elderly. Recombinant vaccines can be chosen for those with egg allergy, and 
so on. This is the approach that should be taken with all vaccines. In some cases it may mean 
merely adjusting the dose based on weight, gender, or age. In other cases it may mean 
utilizing an adjuvanted or non-adjuvanted vaccine based on immune status. Other examples 
include the recently licensed MF59 adjuvanted influenza vaccine (Fluad®), which has 
demonstrably higher immunogenicity and efficacy than its non-adjuvanted counterparts, 
[124–126] or the highly effective AS01-adjuvanted zoster glycoprotein E vaccine, which 
does not contain live virus and may be more broadly suitable for administration to older 
individuals [72, 73].
Thus, the movement toward a new paradigm of vaccine practice, based on a personalized 
approach, is occurring in the 21st century based on new scientific knowledge, market 
demand, safety considerations, immunogenicity concerns, public health trends (age, obesity, 
other), and the simultaneous pull of individualized medicine in other medical arenas. The net 
result is likely to be higher vaccine coverage rates, increased public confidence in vaccines, 
improved immunogenicity and adverse event rates, and a reduction or elimination in the 
morbidity and mortality related to vaccine-preventable diseases. As a result, we anticipate a 
new era of personalized “Predictive Vaccinology,” whereby we abandon a “one size and 
dose fits all vaccine approach” in order to design and develop new vaccines, and acquire the 
ability to make the following predictions for each individual: whether to give a vaccine 
based on likelihood of response (and perhaps need); the likelihood of a significant adverse 
event to a vaccine; and the number of doses likely to be needed to induce a protective 
response to a vaccine [63].
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Figure 1. Personalized Vaccinology Paradigm
Current vaccine development is largely empirical. Vaccines are tested by trial and error, are 
mass produced, and given to the entire population using the same antigen dose, route of 
administration, number of vaccinations, and at the same age.
In contrast, the new vaccine-development paradigm begins with the “Discovery” of new 
knowledge by integrating unbiased, comprehensive analysis of the genome, transcriptome, 
proteome, metabolome, microbiome, and immunome—along with the assessment of 
multiple measures of immune function—in order to understand and evaluate perturbations of 
the immune system. Findings are then “Validated” in replication cohorts or additional model 
systems. The new knowledge is then “Applied” to the creation of new vaccine formulations 
that can undergo additional testing to start a new round of “Discovery,” or can move into 
clinical trials in order to develop vaccine products engineered to elicit (or avoid) specific 
effects on the immune system. Each product is tailored to specific subgroups such that 
robust, protective immunity can be elicited in the old and young, lean and obese, or male and 
female, while avoiding inappropriate immune responses due to genetics, metabolism, race, 
gender, malnutrition, immunosuppression, and other host factors or underlying conditions.
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